

Table 1:

Characteristics	n (%)
<i>Age (years)</i>	
< 1	3 (2.4)
1-4	34 (27.0)
5-9	31 (24.6)
10-14	43 (34.1)
15-18	15 (11.9)
<i>Gender</i>	
Female	58 (46.0)
Male	68 (54.0)
<i>World Bank country income level</i>	
High-income	51 (40.5)
Upper-middle-income	64 (50.8)
Lower-middle-income	11 (8.7)
Low-income	0
<i>CNS tumor diagnosis</i>	
Low grade glioma	25 (19.8)
High grade glioma	18 (14.3)
CNS embryonal tumor	41 (32.5)
Ependymoma	11 (8.7)
CNS germ cell tumor	8 (6.4)
Craniopharyngioma	5 (4.0)
Other intracranial or intraspinal tumor	11 (8.7)
Missing	7 (5.6)
<i>CNS tumor treatment phase</i>	
Active therapy	81 (64.3)
Chemotherapy within 30 days	59 (46.8)
Palliative therapy (including oral chemotherapy)	7 (5.6)
No active treatment	15 (11.9)
Treatment completed	22 (17.5)
Unknown	1 (0.8)

Table 2:

Characteristics	n (%)
<i>Symptoms</i>	
No symptoms	74 (58.7)
Constitutional	38 (30.2)
Respiratory	24 (19.0)
ENT	16 (12.7)
Neurologic	15 (11.9)
Gastrointestinal	6 (4.8)
Dermatologic	1 (0.8)
<i>Comorbidities</i>	
None	101 (80.2)
Recent use of high-dose steroids	5 (4.0)
At least one comorbidity	22 (17.5)
<i>Imaging findings</i>	
No imaging test done	83 (65.9)
Normal findings	21 (16.7)
Abnormal findings	12 (9.5)
Imaging done, unknown findings	2 (1.6)
Unknown	8 (6.4)
<i>ANC (cells/μL)</i>	
ANC > 1000	60 (47.6)
500 < ANC ≤ 1000	5 (4.0)
ANC ≤ 500	17 (13.5)
Missing	44 (34.9)
<i>ALC (cells/μL)</i>	
ALC > 1000	47 (37.3)
500 < ALC ≤ 1000	13 (10.3)
300 < ALC ≤ 500	2 (1.6)
100 < ALC ≤ 300	6 (4.8)
ALC ≤ 100	11 (8.7)
Missing	47 (37.3)
<i>Admission at presentation</i>	
New admission to hospital	33 (26.2)
Patient already admitted	31 (24.6)
No admission required	62 (49.2)

Table 3:

Characteristics	n (%)
<i>Treatment modification</i>	
Not receiving cancer-direct therapy	40 (37.4)
Cancer-directed therapy unmodified	31 (29.0)
Chemotherapy withheld	25 (23.4)
Radiation therapy delayed	7 (6.5)
Neurosurgery was delayed	2 (1.9)
Unknown	3 (2.8)
<i>Highest level of respiratory support</i>	
Room air	95 (88.8)
Nasal cannula/facemask	6 (5.6)
CPAP/BiPAP	1 (0.9)
Intubation	2 (1.9)
Unknown	3 (2.8)
<i>Level of care</i>	
Not admitted to higher level of care	99 (92.5)
Admitted to the intensive care unit	5 (4.7)
Admitted to intermediate care unit	1 (0.9)
Unknown	2 (1.9)
<i>Outcomes at 30 days</i>	
SARS-CoV-2 infection cleared	75 (70.1)
SARS-CoV-2 infection clinically resolved	21 (19.6)
SARS-CoV-2 still positive, asymptomatic	7 (6.5)
Expired due to SARS-CoV-2 infection or its complications	1 (0.9)
Expired, due to other cause	2 (1.9)
Unknown	1 (0.9)

Table 4:

Group	Total	Asymptomatic n (%)	Mild/Moderate n (%)	Severe/Critical n (%)	p Value
Chemotherapy timing					
>30 days	6	3 (50)	3 (50)	0 (0)	0.76
≤30 days	44	27 (61)	14 (32)	3 (7)	
Comorbidity					
None/Unknown	19	11 (58)	7 (37)	1 (5)	0.92
One or more	97	46 (53)	35 (40)	6 (7)	
ANC					
>500 cells/μL	56	27 (48)	26 (46)	3 (5)	0.04
≤500 cells/μL	9	2 (22)	4 (44)	3 (33)	
ALC					
>300 cells/μL	55	26 (47)	25 (45)	4 (7)	0.85
≤300 cells/μL	8	3 (38)	4 (50)	1 (12)	